Stifel Maintains IQVIA Holdings(IQV.US) With Buy Rating, Maintains Target Price $211
A Quick Look at Today's Ratings for IQVIA Holdings(IQV.US), With a Forecast Between $161 to $209
IQVIA Holdings Is Maintained at Neutral by Baird
IQVIA Holdings Is Maintained at Buy by UBS
IQVIA Holdings Price Target Cut to $185.00/Share From $255.00 by UBS
A Quick Look at Today's Ratings for IQVIA Holdings(IQV.US), With a Forecast Between $165 to $168
Leerink Partners Adjusts Price Target on IQVIA Holdings to $210 From $245, Maintains Outperform Rating
IQVIA Hldgs Analyst Ratings
Barclays Maintains Equal-Weight on IQVIA Hldgs, Lowers Price Target to $165
Evercore ISI Sticks to Its Buy Rating for IQVIA Holdings (IQV)
Resilience and Growth Prospects Drive Buy Rating for IQVIA Holdings Amid Industry Challenges
Research Alert: Iqvia Posts Q1 Results, Beats Expectations
Analysts Offer Insights on Healthcare Companies: Mersana Therapeutics (MRSN) and IQVIA Holdings (IQV)
IQVIA Hldgs Analyst Ratings
HSBC Downgrades IQVIA Holdings(IQV.US) to Hold Rating, Cuts Target Price to $160
HSBC Downgrades IQVIA to Hold From Buy, Adjusts Price Target to $160 From $260
Jefferies Maintains IQVIA Holdings(IQV.US) With Hold Rating, Cuts Target Price to $165
BofA Securities Maintains IQVIA Holdings(IQV.US) With Buy Rating, Announces Target Price $190
Resilience and Growth: IQVIA Holdings' Buy Rating Amid RDS Challenges and TAS Strength
Truist Financial Maintains IQVIA Holdings(IQV.US) With Buy Rating, Announces Target Price $216